Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Investors prefer smallcaps, midcaps
Thu, 8 Apr 11:30 am

The Indian markets continued to trade on a weak note during the previous two hours of trade. Currently, selling activity is being witnessed across sectors led by stocks from the banking, power, telecom and metals. Stocks from the realty and software sectors are leading the pack of gainers. Select stocks from the auto sector are able to garner investors' interest.

The BSE-Sensex is trading lower by 50 points while the NSE-Nifty is trading lower by 18 points. However, stocks from the midcap and small cap spaces are trading in the green. The BSE-Midcap and BSE-Smallcap indices are trading higher by 0.4% and 0.9% respectively. The rupee is trading at 44.61 to the US dollar.

Sun Pharma has won USFDA approval to sell a generic version of GlaxoSmithKline Plc's Wellbutrin SR used to treat depressive disorder. The generic Bupropion Hydrochloride tablets include three strengths of 100 milligram (m gm), 150 m gm and 200 m gm. These strengths have combined annual sales of US$ 300 m in the US. This is a positive for the company and will bolster sales from the highly competitive US generics market. It must be noted that in recent times Sun Pharma's US business has been under pressure since its 76% subsidiary Caraco was not compliant with quality manufacturing standards of the US FDA. The stock of Sun Pharma is trading lower currently.

As per a leading business daily, auto major Mahindra & Mahindra has hiked prices of its utility vehicles. The prices have been revised upwards due to Bharat Stage-IV emission norms and partly on account of increase in cost of commodities and fuel prices. M&M has increased the price of its flagship sports utility vehicle Scorpio between Rs 10,300 and Rs 17,500. It has also hiked utility vehicle Bolero's price by Rs 26,100. The company's latest offering Xylo will now be expensive by Rs 15,300 to 15,900.

Auto majors have had to pass on the increase in cost of upgrading cars with newer technology. Apart from M&M, price revision has been undertaken by many other auto majors. The list includes Maruti Suzuki India, Hyundai, General Motors and Toyota. Stocks from the auto sector are trading mixed currently.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Investors prefer smallcaps, midcaps". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.